KYTX
Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.25
−1.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 7.0M |
| Cost of Revenue | 351.0K | — | 2.1M | 1.7M | — |
| Gross Profit | (351.0K) | — | (2.1M) | (1.7M) | 7.0M |
| Operating Expenses | |||||
| R&D Expense | 115.0M | 133.7M | 112.5M | 48.2M | 28.4M |
| SG&A Expense | 43.6M | 36.1M | 30.1M | 12.5M | 8.0M |
| General & Admin Expense | 43.6M | 36.1M | 30.1M | — | 8.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (2.1M) | — | — |
| Total Operating Expenses | 158.6M | 169.8M | 140.5M | 60.7M | 36.4M |
| Cost and Expenses | 158.9M | 169.8M | 142.6M | 62.4M | 36.4M |
| Operating Income (EBIT) | (158.9M) | (169.8M) | (142.6M) | (62.4M) | (29.4M) |
| Non-Operating | |||||
| Interest Income | 8.2M | 9.1M | 15.4M | 2.3M | 565.0K |
| Interest Expense | 1.8M | 489.0K | 142.0K | 187.0K | 65.0K |
| Net Interest Income | 6.4M | 8.6M | 15.2M | 2.1M | 500.0K |
| Other Non-Op Income/Expense | 6.3M | 8.5M | 15.1M | 2.0M | 491.0K |
| Non-Operating Income (excl Interest) | (8.1M) | (9.0M) | (15.3M) | (2.2M) | (556.0K) |
| EBT (Pre-Tax Income) | (152.6M) | (161.3M) | (127.5M) | (60.4M) | (28.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (152.6M) | (161.3M) | (127.5M) | (60.4M) | (28.9M) |
| Earnings from Cont. Ops | (152.6M) | (161.3M) | (127.5M) | (60.4M) | (28.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (152.6M) | (161.3M) | (127.5M) | (60.4M) | (28.9M) |
| Per Share | |||||
| Basic EPS | ($2.94) | ($3.64) | ($3.33) | ($0.00) | ($1.12) |
| Diluted EPS | ($2.94) | ($3.64) | ($3.33) | ($0.00) | ($1.12) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.27 |
| Shares | |||||
| Basic Shares Outstanding | 60.9M | 44.3M | 38.3M | 673.6M | 25.8M |
| Diluted Shares Outstanding | 60.9M | 44.3M | 38.3M | 673.6M | 25.8M |
| Profitability Metrics | |||||
| EBITDA | (149.3M) | (159.0M) | (125.2M) | (58.5M) | (27.8M) |
| D&A | 1.6M | 1.8M | 2.1M | 1.7M | 1.1M |
| EBIT | (150.8M) | (160.8M) | (127.3M) | (60.2M) | (28.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026